News & Updates

Show Multimedia Only

Is first-line lazertinib monotherapy a potential new SoC for EGFRm NSCLC?

Is first-line lazertinib monotherapy a potential new SoC for EGFRm NSCLC?

Patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) exhibited significantly improved progression-free survival (PFS) when treated with lazertinib compared with gefitinib in the first-line setting, results of the LASER301 trial showed.

10 Feb 2023

NPC: Plasma EBV DNA cannot replace nasoendoscopy and biopsy during COVID-19 pandemic

NPC: Plasma EBV DNA cannot replace nasoendoscopy and biopsy during COVID-19 pandemic

Plasma Epstein-Barr virus (EBV) measurement, even when supplemented by imaging, cannot replace nasoendoscopy and biopsy in nasopharyngeal cancer (NPC) management during the COVID-19 pandemic, according to consensus recommendations by an international multidisciplinary group of experts.

Alcohol drinking blamed for rise in colorectal cancer cases among young adults

Alcohol drinking blamed for rise in colorectal cancer cases among young adults

Alcohol drinking blamed for rise in colorectal cancer cases among young adults

Consumption of alcohol appears to be a risk factor for early-onset colorectal cancer and has driven an increase in the incidence of colorectal cancer among young adults, as shown in a study.

10 Feb 2023

Blinatumomab-chemo boosts survival in MRD-negative B-lineage ALL

Blinatumomab-chemo boosts survival in MRD-negative B-lineage ALL

The addition of blinatumomab to chemotherapy extended overall survival (OS) in adults with measurable residual disease (MRD)-negative B-lineage acute lymphoblastic leukaemia (ALL), according to results of the phase III ECOG-ACRIN E1910 trial.

Early rehab makes a difference for children with cancer

Early rehab makes a difference for children with cancer

Participating in an individualized rehabilitation program is beneficial to children with cancer, yielding significant gains in function without any adverse consequences, as reported in a study from Singapore.

Anthracycline treatment for cancer linked to increased risk of congestive heart failure

Anthracycline treatment for cancer linked to increased risk of congestive heart failure

The use of anthracyclines in the treatment of cancer appears to carry a twofold risk of congestive heart failure, according to a study.

Mutational ctDNA analysis helps predict benefit of 2L ripretinib or sunitinib in GIST

Mutational ctDNA analysis helps predict benefit of 2L ripretinib or sunitinib in GIST

Next-generation sequencing (NGS)–based analysis of circulating tumour DNA (ctDNA) helps predict benefit of second-line (2L) ripretinib or sunitinib therapy in patients with imatinib-resistant advanced gastrointestinal stromal tumours (GIST), an exploratory subanalysis of the INTRIGUE trial has shown.

07 Feb 2023

Radiation therapy may raise colorectal cancer risk among Hodgkin's lymphoma survivors

Radiation therapy may raise colorectal cancer risk among Hodgkin's lymphoma survivors

Individuals who received radiation therapy for Hodgkin's lymphoma are at increased risk of colorectal cancer, as reported in a study.

06 Feb 2023

SPOTLIGHT shines on zolbetuximab-chemo potential for gastric/GEJ cancer

SPOTLIGHT shines on zolbetuximab-chemo potential for gastric/GEJ cancer

A combination regimen comprising zolbetuximab and mFOLFOX6* chemotherapy (CT) regimen showed potential as first-line treatment for claudin-18.2-positive**/HER2-negative (CLDN18.2+/HER2–) locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, according to the primary findings of the phase III SPOTLIGHT trial.

06 Feb 2023

Hormone therapies up ILD events in men with prostate cancer

Hormone therapies up ILD events in men with prostate cancer

Hormone therapy drugs, such as bicalutamide, flutamide, nilutamide, goserelin, degarelix, and apalutamide, appear to increase the likelihood of developing interstitial lung disease (ILD) events in patients with prostate cancer, reports a study.

04 Feb 2023

Something went wrong.